Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...

Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from Equal Weight, ...

Cloud-based Elite platform to roll out to Roche's laboratory network across 50+ countries and a target 1,000 installations over five years. BASEL, Switzerland, March 18, 2025 /PRNewswire/ ...

Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

In March 2025, Zealand Pharma and Roche entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and ...

Welcome to professors’ picks, offering a weekly curated selection of FT articles by and for business school faculty to ...

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Switzerland's Roche announced on the 12th (local time) that it has signed a contract to acquire the technology for the obesity drug candidate 'petrelintide' from Denmark's biotech Zealand Pharma. If ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...